Safety Profile of Anti-CD38 Monoclonal Antibodies in MM

IMWG Conference Series: Reporting from ASH 2022Подробнее

Anti-CD38 monoclonal antibodies – a new drug class for treating myelomaПодробнее

The impact of the addition of anti-CD38 monoclonal antibodies to the frontline treatment of myelomaПодробнее

CD38 Antibodies in Multiple Myeloma: What Next?Подробнее

Mezagitamab: an anti-CD38 antibody for R/R MMПодробнее

The importance of anti-CD38 monoclonal antibodies for multiple myelomaПодробнее

Mechanisms of action of CD38 antibodies in myelomaПодробнее

Daratumumab Safe in Relapsed/Refractory Multiple Myeloma PatientsПодробнее

Anti-CD38 immunotherapy treatment for multiple myelomaПодробнее

IACH Webinar Series: Anti-CD38 monoclonal antibodies in multiple myelomaПодробнее

Multiple Myeloma | What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of M...Подробнее

Monoclonal antibodies for multiple myelomaПодробнее

A myeloma magnifying glass? CD38-targeted Immuno-PETПодробнее

Antibodies in Practice: SLAMF-7, CD38, Bispecific?Подробнее

Reaching the Next Level of Myeloma Patient Care: Antibody Therapy and Novel Mechanisms of ActionПодробнее

Dr. Angela Dispenzieri Discusses Anti-CD38 Monoclonal Antibodies in MyelomaПодробнее

Phase Ib final analysis — Isatuximab + carfilzomibПодробнее

Safety of Monoclonal Antibodies in MyelomaПодробнее

MYELOMA UNIVERSITY | Monoclonal Antibodies as Treatment for Multiple MyelomaПодробнее

A retrospective study analyzing outcomes of patients with anti-CD38 refractory myelomaПодробнее